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Background: Little is known about the cognitive profile of Hereditary Spastic Paraplegias
(HSP), where most scientific attention has been given to motor features related to
corticospinal tract degeneration.
Objectives: We aimed to perform a broad characterization of the cognitive functions
of patients with pure and complicated HSP as well as to determine the frequency of
abnormal cognitive performances in the studied subtypes.
Methods: A two-center cross-sectional case-control study was performed. All
individuals underwent cognitive assessment through screening tests (Mini Mental State
Examination—MEEM and Montreal Cognitive Assessment—MOCA) and tests to assess
specific cognitive functions (Verbal fluency with phonological restriction—FAS; Verbal
categorical fluency—FAS-cat and Rey’s Verbal Auditory Learning Test -RAVLT).
Results: Fifty four patients with genetically confirmed HSP diagnosis, 36 with spastic
paraplegia type 4 (SPG4), 5 SPG11, 4 SPG5, 4 cerebrotendinous xanthomatosis (CTX),
3 SPG7 and 2 SPG3A, and 10 healthy, unrelated control subjects, with similar age,
sex, and education participated in the study. SPG4 patients had worse performances
in MOCA, FAS, FAS-cat, and RAVLT when compared to controls. Most SPG4 patients
presented cognitive changes not compatible with dementia, performing poorly in
memory, attention and executive functions. SPG5 patients scored lower in executive
functions and memory, and SPG7 patients performed poorly on memory tasks. All
evaluated cognitive functions were markedly altered in CTX and SPG11 patients.
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Conclusions: Cognitive abnormalities are frequent in HSP, being more severe in
complicated forms. However, cognitive impairments of pure HSPs might impact
patients’ lives, decreasing families’ socioeconomic status and contributing to the overall
disease burden.
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INTRODUCTION
Hereditary Spastic Paraplegias (HSP) is a heterogeneous group
of neurodegenerative genetic diseases (> 80 loci have been
described) with spastic gait as the core feature (1, 2). HSP
subtypes are clinically classified into pure forms—in which
only a pyramidal syndrome is found (although changes in
vibratory sensation and neurogenic bladder are accepted)—
and complicated forms in which pyramidal findings are
accompanied by dysfunction in other neurological systems (e.g.,
ataxia, parkinsonism, cognitive impairment, etc.) or by systemic
involvement (3).
Although HSP are rare conditions, recent studies suggest that
its prevalence (2–10 per 100,000) is similar to or higher than
that of more studied conditions such as hereditary ataxias (4).
Spastic paraplegia type 4 (SPG4) is the most frequent autosomal
dominant subtype, whereas SPG11 and SPG7 are the most
frequent autosomal recessive subtypes of HSP worldwide (4, 5).
There are few studies that have investigated the cognitive
profile of HSP patients. Most of then focused on complicated
forms, reporting intellectual disability and cognitive deficits
perceptible by physician’s clinical evaluation in up to 100%
of SPG11 patients (6, 7). On the other hand, the cognitive
characterization of the pure forms of HSP remains unclear, with
some reports describing mild cognitive changes without the use
of tests to evaluate specific cognitive functions or only being
described through the physician’s clinical impression (2, 6–11).
Thus, the objective of this study was to characterize the cognitive
functions of memory, orientation, verbal fluency, language,
attention, and executive functions in HSP patients, to determine
the frequency of cognitive changes in the different subtypes, and
to correlate these findings with disease severity variables.
MATERIALS AND METHODS
Design and Subjects
We performed a two-center, exploratory, cross-sectional, case-
control study conducted at two teaching hospitals in the
Brazilian cities of Porto Alegre and Campinas. We included
consecutive patients followed at the Neurogenetics outpatient
clinics of these hospitals, from December 2016 to August 2018,
and who presented genetically confirmed diagnosis of HSP
or genetic or biochemical diagnosis of CTX, which can be
considered as a complicated form of HSP (5). Healthy, unrelated
subjects, with similar sex, age, and education characteristics
were recruited from the local community of Porto Alegre
as the control group for the adult population. Concomitant
neurological or systemic conditions that could present cognitive
alterations were exclusion criteria. The project was approved
by the institutions’ ethics committees under review numbers
170012 and 62653816.7.0000.5404, which follows the Declaration
of Helsinki. Informed written consent was obtained from all
individuals’ prior participation.
Cognitive Evaluation
Cognitive assessments were performed by a single evaluator
(LAJS) through standardized tests validated for the Brazilian
population, which analyze a range of competencies, namely:
2.1 Mini Mental State Examination (MMSE): screening test
for cognitive function evaluation. The maximum score is
30 points and, in the Brazilian population, a score of 28
points or more is indicative of normal cognitive function
for individuals who have been formally educated for >8
years (12).
2.2 Montreal Cognitive Assessment (MoCA): screening test for
cognitive function evaluation. The maximum score is 30
points and a score of 26 point or more is indicative of normal
cognitive function (13).
2.3 Verbal fluency with phonological restriction (FAS): it
consists in naming words beginning with the letters F, A, and
S, respectively, and assesses executive function, language and
semantic memory. Performance can be affected by education
and by age (14).
2.4 Verbal categorical fluency (animals) (FAS-cat): this measure
is a variation of the verbal fluency test and it is restricted
to a semantic category. The score may be affected by
education (15).
2.5 Rey’s Verbal Auditory Learning Test (RVALT): is a tool
to assess immediate memory (RVALT) as well as short
(A6) and long-term (A7) retention. The test involves five
consecutive repetitions and retrievals of stimuli from a list
of 15 words (16).
Cognitive performance for the study population under 17 years-
old was evaluated with the Wechsler Intelligence Scale for
Children (WISC III) (17). This test can be used as an IQ
(Intelligence Quotient) test for children and it is most often used
as a clinical tool to measure individual’s cognitive abilities. We
used the Cubes and Vocabulary subtests to evaluate children’s
performance. Dementia diagnosis was based on Diagnostic and
Statistical Manual of Mental Disorders (DSM-V) (18) criteria.
Evaluation of Depressive Symptoms
In order to verify if depressive symptoms could act as
a confounding factor for cognitive performance, the Beck
Depression Inventory (BDI) was applied. BDI is a self-reported
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Female sex 6 (60%) 17 (47%) 2 (40%) 4 (80%) 2 (50%) 2 (50%) 1 (33%) 2 (100%)
Age 46.5 (12.3) 45 (18) 9 (2.9) 36.4 (5.7) 47.5 (10.5) 54 (6.5) 53.3(25.6) 38.5 (17.7)
Educational level 9.4 (3.1) 7.16 (3.9) 3.8 (3.11) 10 (2.8) 8 (4.8) 4.5 (1) 16.3 (1.6) 9 (4.2)
Age at onset – 34.7 (16.8) 1.75 (1.30) 17.4 (2.8) 25.7 (20.2) 34 (4.9) 21.7(12.5) 11.5 (0.7)
Disease duration – 16.4 (11.3) 8.2 (2.77) 20.4 (4.2) 22 (16.9) 21.2(5.4) 32.3(17.5) 27 (18.4)
SPRS – 18.7 (9.8) 11.4 (5.9) 37.2 (6.1) 27 (16.1) 33.2 (11.2) 22.6(10.6) 8.5 (3.5)
Disease stage – 0–0 (0%) 0–0 (0%) 0–0 (0%) 0–0 (0%) 0–0 (0%) 0–0 (0%) 0–0 (0%)
1–1 (3%) 1–2 (40%) 1–0 (0%) 1–1 (25%) 1–0 (0%) 1–0 (0%) 1–1 (50%)
2–5 (16%) 2–3 (60%) 2–0 (0%) 2–1 (25%) 2–0 (0%) 2–0 (0%) 2–0 (0%)
3–8 (26%) 3–0 (0%) 3–0 (0%) 3–0 (0%) 3–1 (25%) 3–1(33%) 3–1 (50%)
4 −15(49%) 4–0 (0%) 4–1 (20%) 4–1 (25%) 4–3 (75%) 4–2(66%) 4–0 (0%)
5–2 (6%) 5–0 (0%) 5–4 (80%) 5–1 (25%) 5–0 (0%) 5–0 (0%) 5–0 (0%)
Cross-sectional disease
progression
– 1.13 1.39 1.82 1.22 1.56 0.48 0.31
BDI – 8.6 (5.9) NA NA 9 (1) 4.75 (3.6) 6.3 (5.5) 7 (1.4)
Data are shown as means in years (standard deviation), except for sex and disease stage that are shown as frequencies. CTX, cerebrotendinous xanthomatosis; SPRS, Spastic
Paraplegia Rating Scale; BDI, Beck Depression Inventory; NA, not available—patients unable to perform this test.
questionnaire composed of 21 questions that assess the intensity
of depressive symptoms. Scores range from 0 to 63 points that are
crescent in severity (19).
Motor Neurological Evaluation
Neurological severity was assessed by the Brazilian Portuguese
version of the Spastic Paraplegia Rating Scale (SPRS). SPRS scores
ranges from 0 to 52 and are crescent in severity (20). Disease
stage was classified as: (0) asymptomatic; (1) no functional
handicap, but signs at examination (slight gait stiffness); (2)
mild gait stiffness, walking unlimited, and running still possible;
(3) moderate gait stiffness, limited walking without aid, and
running impossible; (4) moderate to severe gait stiffness, walking
possible with aid; and (5) walking impossible, wheelchair bound.
We also estimated the cross-sectional disease progression as the
cross-sectional quotient of disease severity (SPRS) and disease
duration, as previously established (2). Disease duration and age
of onset of the first motor symptomwere reported by patients and
their relatives.
Statistical Analysis
Statistical tests were selected according to the distribution of
data given by Shapiro-Wilk test and histograms. Descriptive
analysis of cognitive assessment scores was carried out based
on the tests cut-offs for normal performance according to age
and education level in the Brazilian population. Comparisons
between SPG4 and controls individuals’ scores and between SPG4
patients with truncating and non-truncating variants scores
were performed by Student’s t-test or Mann–Whitney U-test.
The 95% confidence interval (CI) for differences in means
between groups was also provided. Correlations of cognitive
performance scores with independent variables (age, education
level, age at onset, SPRS, disease stage, disease duration, cross-
sectional disease progression) were performed with the Pearson
or Spearman correlation tests. A linear regression model was
built with independent variables that presented P < 0.2 in the
simple correlation test, where only variables that maintained P <
0.05 after adjustment for covariates were kept in the final model.
Statistical significance was defined as P < 0.05.
RESULTS
A total of 54 patients with HSP were enrolled in the
study, including 36 (5 children) SPG4 (17 families), 5 SPG11
(4 families), 4 SPG5 (1 family), 4 CTX (4 families), 3
SPG7 (3 families), and 2 SPG3A (1 family) patients and
10 healthy control subjects. See Table 1 for the clinical and
demographical characterization of the study population and
Supplementary Table 1 (21–26) for detailed individual data
of subjects.
Patients’ Performance in Relation to
Cognitive Test Scores
Table 2 details the cognitive performance of HSP patients
and controls. Most SPG4 patients presented cognitive changes
not compatible with dementia, performing poorly in memory,
attention and executive function. SPG5 patients scored lower in
executive functions and memory, and SPG7 patients performed
poorly on memory tasks, also presenting cognitive changes not
compatible with dementia. All evaluated cognitive functions
were altered in patients with CTX (2/4 with dementia) and
SPG11 (all with dementia) patients. The 2 patients with SPG3A
performed within normal limits on cognitive tests. Of note,
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40% 96% 75% 66% 100% 75% 0%
Data are shown as means (standard deviation), except for MMSE and A7 that are shown in median (interquartile range), and percentages of altered performances according to the
normal standards for the given test. CTX, cerebrotendinous xanthomatosis; FAS, verbal fluency with phonological restriction; FAS-cat, verbal categorical fluency (animals); MMSE, Mini
Mental State Examination; MOCA, Montreal Cognitive Assessment; RVALT, A6 and A7, Rey’s Verbal Auditory Learning Test.
aOnly adult patients with SPG4 were considered.
SPG11 patients were unable to respond to BDI, because of
cognitive impairment.
Comparative Analysis Between SPG4 and
Control Subjects
While the performance of SPG4 patients was similar to controls
in the MMSE (P = 0.800, Figure 1A), their scores were
lower than those of the control subjects in all other cognitive
tests: MOCA (−4.93, 95% CI, −8.20 to −1.66, P = 0.004,
Figure 1B), FAS (−12.62, 95% CI, −19.54 to −5.70, P = 0.001,
Figure 1C), FAScat (−6.32, 95% CI, −9.96 to −2.68, P = 0.001,
Figure 1D), RAVLT (−15.05, 95% CI, −21.22 to −8.92, P <
0.001, Figure 1E), A6 (−4.26, 95% CI,−6.04 to−2.48; P < 0.001,
Figure 1F) and A7 (P < 0.001, Figure 1G).
Which Factors Correlated to Cognitive
Decline in SPG4 Patients?
Although no statistically significant difference was found
between SPG4 patients and control subjects in MMSE, both
disease duration (Beta = −0.351, 95% CI, −0.170 to −0.014,
R2 = 0.116, P = 0.022, Figure 2A) and education years (Beta
= 0.492, 95% CI, 0.152 to 0.614, R2 = 0.227, P = 0.002) were
independently correlated with MMSE in the linear regression
model. For each additional year of disease duration, there was
a decrease of 0.092 points in MMSE, and for each additional
education year there was an increase of 0.383 points in the
MMSE results. Education and disease duration were also the
only variables independently correlated in the linear regression
model with MOCA. For each additional year of disease duration
there was a decrease of 0.162 points in MOCA (Beta = −0.382;
95% CI, −0.294 to −0.030, R2 = 0.137, P = 0.018, Figure 2B),
and for each additional education year there was an increase of
0.525 points in MOCA (Beta = 0.416, 95% CI, 0.134 to 0.916,
R2 = 0.163, P = 0.01). Age was the only variable correlated with
FAS (R = −0.520, P = 0.003) and RAVLT (R = −0.428, P =
0.016), and neither significant correlations were found between
the independent variables and performances in the FAScat, nor
A6 and A7. BDI scores did not correlate with cognitive tests
performance (P > 0.2 for all comparisons), making it very
unlikely that depressive symptoms were influencing the results
of the cognitive evaluation.
Genotype-Phenotype Correlation in SPG4
Variants in SPAST were classified as truncating (nonsense and
frameshift variants, N=11 individuals) and non-truncating
(missense and in-frame insertion, N=20 individuals).
Clinical, demographical and cognitive findings of patients
with truncating and non-truncating variants did not differ; see
Supplementary Table 2 for details.
Cognitive Performance in Children
The WISC-III results showed low average IQ scores in 60%
(3/5) of the children with SPG4 and average IQ in the others.
There were no children in the other HSP subtypes. Mean cubes
subtest (executive subscale) performance was 9.2 (4.16) andmean
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FIGURE 1 | Comparison between control and SPG4 subjects performances in
cognitive tests. Bars represent mean values and standard deviation. Box-plots
represent median values and interquartile ranges. **P < 0.01 e ***P ≤ 0.001.
FAS, verbal fluency with phonological restriction; FAS-cat, verbal categorical
fluency (animals); MMSE, Mini Mental State Examination; MoCA, Montreal
Cognitive Assessment; RVALT, A6 and A7, Rey’s Verbal Auditory Learning
Test. (A) MEEM, (B) MOCA, (C) FAS, (D) FAS-cat, (E) RVALT, (F) A6 -
short-term retention, (G) A7 - long-term retention.
vocabulary test (verbal subscale) was 7.2 (2.51), which are low
average values. All evaluated children had missense pathogenic
variants in SPAST.
DISCUSSION
Over the last years, non-motor symptoms of movement disorders
have received greater attention (27, 28), albeit in a more
timid manner for hereditary spastic paraplegias (29). Classically
the pure forms of HSP have been described as solely motor
syndromes in which only pyramidal signs are found. However,
these descriptions are generally based on the neurologist’s
impression, without a more formal assessment of non-motor
symptoms, such as subtle cognitive changes (2). In this study,
we found impairments in memory, attention, executive functions
and verbal fluency in SPG4 patients, the most prevalent HSP
subtype worldwide and the prototype of pure forms of the
disease, and we confirmed the more severe cognitive dysfunction
of complicated forms of HSP.
We found cognitive changes not compatible with dementia
in most evaluated SPG4 patients, with abnormal cognitive
performances ranging from 41 to 96%, depending on the utilized
test and domain, with memory (immediate and recent) being
the most frequently altered cognitive function. Our results are
partially in agreement with descriptions of subtle cognitive
deficits in these patients in a few case series (2, 7, 8, 10,
11). The inverse correlation between MMSE and MOCA with
disease duration and the normal, albeit low average, performance
in children on intelligence tests might suggest that cognitive
dysfunction in SPG4 is progressive and worsens with disease
progression. SPG4 patients with truncating and with non-
truncating variants had similar cognitive performances, which is
in agreement with a previous study (8).
Neuroimaging findings from previous studies (30, 31) are in
agreement with the cognitive changes we have found, suggesting
a more widespread central nervous system involvement in
SPG4. Extensive fractional anisotropy reduction in non-motor
regions (posterior cingulate gyri and splenium of the corpus
callosum) were found in SPG4 patients on magnetic resonance
(MRI) diffusion tensor imaging (30), as well as decreased
brain activity in the left insular cortex in functional MRI
(31), which regulates a wide range of cognitive and emotional
functions (32).
Despite the cognitive impairment of SPG4 patients in
the overall evaluation, no differences to controls were found
with MMSE screening test. On the other hand, most SPG4
patients (87%) scored below normal thresholds for MOCA. The
discrepancy of MMSE and MOCA was also verified among
patients with SPG5 and SPG7 and was suggested by a previous
study, even though this particular tool was not used by that
authors (10). Therefore, MOCA is likely to be a more sensitive
screening tool for cognitive changes in HSP, especially for
pure forms.
Most SPG11 and CTX patients presented major cognitive
deficits and scores well below what would be expected for all
cognitive functions tested (not only memory). These results
corroborate previous findings of severe intellectual disability
in this population confirming the higher prevalence and
severity of cognitive dysfunction when compared to pure HSP
forms (33, 34).
Due to the exploratory nature of the study we neither
performed sample size calculation nor definition of the study
power and main outcome. Nevertheless, statistically significant
differences between SPG4 and controls were found in all tests,
except MMSE. There was no trend for lower MMSE scores in
SPG4 (P= 0.800) when compared to controls and therefore there
is a low chance of Type 2 error. Finally, we should mention
that we were unable to compare the cognitive performances of
children and adults due to the different nature of cognitive tests
according to age.
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FIGURE 2 | Correlation of (A) MMSE and (B) MOCA with disease duration in SPG4. Simple correlation of MMSE and MOC with disease duration in SPG4. MMSE,
Mini Mental State Examination; MoCA, Montreal Cognitive Assessment.
CONCLUSION
Cognitive abnormalities are frequent in HSP, with dementia
being commonly observed in complicated forms and cognitive
changes not compatible with dementia in pure forms of the
disease. SPG4, the most frequent and the prototype of pure
HSP, present multiple cognitive abnormalities that might impact
patients’ lives and result in difficulties at school, on their
careers and, consequently, might decrease patients’ and families’
socioeconomic status. Longitudinal studies are needed to assess
the rate of progression of cognitive changes and to verify whether
motor and cognitive functions have similar or different patterns
of progression and thus different pathophysiological processes.
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